資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/29615
|
| 題名: | Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+ ATPase G1 subunit |
| 作者: | Lin, CW;Tsai, FJ;Wan, L;Lai, CC;Lin, KH;Hsieh, TH;Shiu, SY;Li, JY |
| 貢獻者: | 健康照護學院醫技系;China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung 404, Taiwan;China Med Univ Hosp, Dept Lab Med, Clin Virol Lab, Taichung 404, Taiwan;China Med Univ Hosp, Dept Med Genet & Med Res, Taichung 404, Taiwan |
| 日期: | 2005 |
| 上傳時間: | 2010-09-24 14:38:54 (UTC+8) |
| 出版者: | ELSEVIER SCIENCE BV |
| 摘要: | Context: Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia. Objective: To determine whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor-enhancing agents have beneficial effects for acute exacerbation of schizophrenia. Design: Randomized, double-blind, placebo-controlled trial. Setting: Inpatient units of 2 major medical centers in Taiwan. Patients: Sixty-five schizophrenic inpatients with acute exacerbation. Interventions: Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy. Main Outcome Measures: Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) (20 and 17 items) total scores. Results: The sarcosine group revealed more reductions in PANSS total scores than the placebo (P=.04) and D-serine (P <.001) groups. Sarcosine adjunctive treatment was also superior to placebo in reducing SANS-20 (P=.007) and SANS-17 (P=.003) scores and to D-serine in decreasing SANS-20 (P=.006) and SANS-17 (P=.002) scores. The PANSS-general, PANSS-cognitive, and PANSS-depressive symptoms scores and SANS-alogia and SANS-blunted affect scores improved significantly more in sarcosine-cotreated patients than in risperidone monotherapy patients (P <=.02 for all). Sarcosine adjunctive therapy also surpassed D-Serine in terms of PANSS-general, PANSS-positive, PANSS-negative, and PANSS-depressive symptoms scores (P <=.04 for all). D-Serine and risperidone cotreatment did not differ significantly from risperidone monotherapy in all efficacy domains. Conclusions: This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia. This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase. Further studies are needed. |
| 關聯: | FEBS LETTERS 579(27):6089-6094 |
| 顯示於類別: | [醫學檢驗生物技術學系暨碩士班 ] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
